Department of Oncology

Mission of Oncology Department

To give people with cancer and blood disorders personalized, family-focused, patient-centered, multidisciplinary care that is driven by results and value and is improved by innovative and practice-based research in an academic setting.

Vision of Oncology Department

To develop a premiere, comprehensive oncology center to become a global leader in clinical care, research, and education.

Divisions of Oncology Department

• Adult Hematology Division
  

• Adult Medical Oncology Division

• Gynecology Oncology Division

• Radiation Oncology Division

• Palliative Care Division

• Stem Cell Transplant and Cellular Therapy Division

• Cancer Control and Outreach Division

Other Services:

• Data Management Unit
  

• Research Unit

• Quality and Patient Safety Unit

• Oncology ICU

Main millstone, Achievements and Awards of Oncology Department

• The department has catered to a total of 42,714 patients in all outpatient services including Chemo Clinic (suites) and Day Care services.

• The department has provided in-patient services to a total of 2,052 patients in all services (Jan. – Aug. 2021).
  

Research and Publications

The department has achieved 21 Publications

(17 full text and 4 abstracts publications)

1. Alshammari K, Aung KL, Zhang T, Razak ARA, Serra S, Stockley T, et al. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clin Colorectal Cancer [Internet]. 2021;1–8. Available from:https://doi.org/10.1016/j.clcc.2021.07.004

2. Alyabsi M, Ramadan M, Algarni M, Alshammari K, Jazieh AR. The effect of marital status on stage at diagnosis and survival in Saudis diagnosed with colorectal cancer: cancer registry analysis. Sci Rep [Internet]. 2021;11(1):1–10. Available from: https://doi.org/10.1038/s41598-021-88042-9
3. Alyabsi M, Sabatin F, Ramadan M, Jazieh AR. Colorectal cancer survival among Ministry of National Guard-Health Affairs ( MNG-HA ) population 2009 – 2017 : retrospective study. 2021;1–11.
4. Jazieh AR, Abuelgasim KA, Ardah HI, Alkaiyat M, Da'ar OB. The trends of complementary alternative medicine use among cancer patients. BMC Complement Med Ther. 2021;21(1):1–8.
5. El Fakih R, Haroon A, Alfraih F, Al-Khabori MK, Alzahrani M, Alhuraiji A, et al. Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East. Bone Marrow Transplant [Internet]. 2021;56(9):2144–51. Available from: http://dx.doi.org/10.1038/s41409-021-01312-y
6. Zekri J, Saadeddin A, Alharbi H. Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study. BMC Womens Health [Internet]. 2021;21(1):1–10. Available from: https://doi.org/10.1186/s12905-020-01159-3
7. Salama H, Al Mutairi N, Damlaj M, Alolayan A, Binahmed A, Salama H, et al. Reducing Futile Acute Care Services for Terminally Ill Patients With Cancer: The Dignity Project. JCO Oncol Pract. 2021;OP.20.00922. *** Both Researc and QI Project
8. Jazieh AR, Coutinho AK, Bensalem AA, Alsharm AA, Errihani H, Mula-Hussain L, et al. Impact of the COVID-19 Pandemic on Oncologists: Results of an International Study. JCO Glob Oncol. 2021;(7):242–52.
9. Alahmari B, Alzahrani M, Al Shehry N, Tawfiq O, Alwasaidi T, Alhejazi A, et al. Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation. JCO Glob Oncol. 2021;(7):1220–32.
10. Abuelgasim KA, Shammari R Al, Alshieban S, Alahmari B, Alzahrani M, Alhejazi A, et al. Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience. Leuk Res Reports [Internet]. 2021;15(April):100240. Available from: https://doi.org/10.1016/j.lrr.2021.100240
11. Jazieh AR, Alghamdi M, Alkaiyat M, Al Johani SM, Damlaj M. A retrospective evaluation of the value of COVID-19 screening and testing in patients with cancer: Aiming at a moving target. J Infect Public Health [Internet]. 2021;14(7):949–53. Available from: https://doi.org/10.1016/j.jiph.2021.05.005
    
12. Alzahrani M, Damlaj M, Jeffries N, Alahmari B, Singh A, Rondelli D, et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol. 2021;192(4):761–8.
13. Bukhari N, Alshangiti A, Tashkandi E, Algarni M, Al-Shamsi HO, Al-Khallaf H. Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature. Clin Pract. 2021;11(3):467–71.
14. Journal AM, Journal AM, Ahmed AK. Impact of the COVID-19 Pandemic on Cancer Care in Iraq: Exploratory Research. Al-Anbar Med J. 2021;17(1):9–15.
15. Alkushi A, Omair A, Masuadi E, Alamri G, Abusanad A, Abdelhafiez N, et al. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings. Cureus. 2021;13(2).
16. Benbrahim Z, Mula-Hussain L, Al-Shamsi HO, Saghir N El, Asiri M Al, Bahrani B Al, et al. National approaches to managing cancer care: Responses of countries in the MENA region to the COVID-19 pandemic. Ecancermedicalscience. 2021;15:1–10.
17. Jazieh AR, Bensalem AA, Bounedjar A, Benbrahim Z, Mohamed O. Predictors of poor precautionary practices towards COVID-19 among cancer patients. 2021;
18. Alyabsi M, Algarni M, Alshammari K. Trends in Colorectal Cancer Incidence Rates in Saudi Arabia (2001–2016) Using Saudi National Registry: Early- Versus Late-Onset Disease. Front Oncol. 2021;11(September):1–9.
19. Abuelgasim KA, Damlaj M, Bosaeed M, Altamimi S, Abdullah H, Ramli RM, et al. Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2021 [Internet]. 2021 Sep 10 [cited 2021 Sep 15];1–3. Available from: https://www.nature.com/articles/s41409-021-01457-w